ZA200410407B - Cyclothiocarbamative derivatives as PR modulators and use thereof for treatment of skin disorders - Google Patents
Cyclothiocarbamative derivatives as PR modulators and use thereof for treatment of skin disorders Download PDFInfo
- Publication number
- ZA200410407B ZA200410407B ZA200410407A ZA200410407A ZA200410407B ZA 200410407 B ZA200410407 B ZA 200410407B ZA 200410407 A ZA200410407 A ZA 200410407A ZA 200410407 A ZA200410407 A ZA 200410407A ZA 200410407 B ZA200410407 B ZA 200410407B
- Authority
- ZA
- South Africa
- Prior art keywords
- substituted
- dihydro
- alkyl
- dimethyl
- group
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 25
- 208000017520 skin disease Diseases 0.000 title claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 146
- 229910052799 carbon Inorganic materials 0.000 claims description 125
- 125000003545 alkoxy group Chemical group 0.000 claims description 64
- 229910052739 hydrogen Inorganic materials 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 54
- 125000005842 heteroatom Chemical group 0.000 claims description 53
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 50
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 50
- 125000000623 heterocyclic group Chemical group 0.000 claims description 48
- 150000001875 compounds Chemical class 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 38
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 125000003107 substituted aryl group Chemical group 0.000 claims description 26
- 125000004001 thioalkyl group Chemical group 0.000 claims description 25
- 206010000496 acne Diseases 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 13
- 150000001721 carbon Chemical class 0.000 claims description 13
- 239000002207 metabolite Substances 0.000 claims description 12
- 239000000651 prodrug Substances 0.000 claims description 12
- 229940002612 prodrug Drugs 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 206010020112 Hirsutism Diseases 0.000 claims description 8
- 230000003750 conditioning effect Effects 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- 150000001555 benzenes Chemical group 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 208000028257 Joubert syndrome with oculorenal defect Diseases 0.000 claims description 3
- 238000002657 hormone replacement therapy Methods 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 239000002379 progesterone receptor modulator Substances 0.000 claims description 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 37
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- PYVFWTPEBMRKSR-UHFFFAOYSA-N tanaproget Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 PYVFWTPEBMRKSR-UHFFFAOYSA-N 0.000 claims 5
- 230000001419 dependent effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 229940011871 estrogen Drugs 0.000 claims 4
- 239000000262 estrogen Substances 0.000 claims 4
- 230000001613 neoplastic effect Effects 0.000 claims 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 239000005556 hormone Substances 0.000 claims 3
- 229940088597 hormone Drugs 0.000 claims 3
- JWRMZXFZQZVKSD-UHFFFAOYSA-N 3-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-5-fluorobenzonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(F)=CC(C#N)=C1 JWRMZXFZQZVKSD-UHFFFAOYSA-N 0.000 claims 2
- CUQLFUMXNAKZSH-UHFFFAOYSA-N 3-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)benzonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC(C#N)=C1 CUQLFUMXNAKZSH-UHFFFAOYSA-N 0.000 claims 2
- RILXTHFMVLBOPN-UHFFFAOYSA-N 3-(8-bromo-4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-5-fluorobenzonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=C(Br)C=C1C1=CC(F)=CC(C#N)=C1 RILXTHFMVLBOPN-UHFFFAOYSA-N 0.000 claims 2
- YLRADUODZWLKHG-UHFFFAOYSA-N 3-fluoro-5-(8-fluoro-4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)benzonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=C(F)C=C1C1=CC(F)=CC(C#N)=C1 YLRADUODZWLKHG-UHFFFAOYSA-N 0.000 claims 2
- FEWVQKWESAUNPQ-UHFFFAOYSA-N 4,4-dimethyl-6-(3-nitrophenyl)-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC([N+]([O-])=O)=C1 FEWVQKWESAUNPQ-UHFFFAOYSA-N 0.000 claims 2
- OEVOYVHAFYXKNX-UHFFFAOYSA-N 4-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)furan-2-carbonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=COC(C#N)=C1 OEVOYVHAFYXKNX-UHFFFAOYSA-N 0.000 claims 2
- UCEMKOZZXFXATD-UHFFFAOYSA-N 4-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)thiophene-2-carbonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CSC(C#N)=C1 UCEMKOZZXFXATD-UHFFFAOYSA-N 0.000 claims 2
- JSOJTUILYANJMW-UHFFFAOYSA-N 4-benzyl-6-(3-chlorophenyl)-4-methyl-1h-3,1-benzoxazine-2-thione Chemical compound O1C(=S)NC2=CC=C(C=3C=C(Cl)C=CC=3)C=C2C1(C)CC1=CC=CC=C1 JSOJTUILYANJMW-UHFFFAOYSA-N 0.000 claims 2
- MQYRSOFJNHXZHN-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-1-ethylpyrrole-2-carbonitrile Chemical compound CCN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 MQYRSOFJNHXZHN-UHFFFAOYSA-N 0.000 claims 2
- HYELXXFFGVQXLM-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-1h-pyrrole-2-carbonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(C#N)N1 HYELXXFFGVQXLM-UHFFFAOYSA-N 0.000 claims 2
- JXEZBFHBHFDRCM-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-4-methylthiophene-2-carbonitrile Chemical compound C1=C(C#N)SC(C=2C=C3C(C)(C)OC(=S)NC3=CC=2)=C1C JXEZBFHBHFDRCM-UHFFFAOYSA-N 0.000 claims 2
- YULOLNRYBCOJDS-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-4-propylthiophene-2-carbonitrile Chemical compound C1=C(C#N)SC(C=2C=C3C(C)(C)OC(=S)NC3=CC=2)=C1CCC YULOLNRYBCOJDS-UHFFFAOYSA-N 0.000 claims 2
- XSBJYXLVQYKJTL-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)thiophene-2-carbonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(C#N)S1 XSBJYXLVQYKJTL-UHFFFAOYSA-N 0.000 claims 2
- IUJHXSNSAUOSSH-UHFFFAOYSA-N 6-(2-chlorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC=C1Cl IUJHXSNSAUOSSH-UHFFFAOYSA-N 0.000 claims 2
- WYHOTGLZCWQZME-UHFFFAOYSA-N 6-(3-bromophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC(Br)=C1 WYHOTGLZCWQZME-UHFFFAOYSA-N 0.000 claims 2
- IUQHQDMKFBMQME-UHFFFAOYSA-N 6-(3-chloro-4-fluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(F)C(Cl)=C1 IUQHQDMKFBMQME-UHFFFAOYSA-N 0.000 claims 2
- HWFFFZIEYMMDDC-UHFFFAOYSA-N 6-(3-chlorophenyl)-4,4-diethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(CC)(CC)OC(=S)NC2=CC=C1C1=CC=CC(Cl)=C1 HWFFFZIEYMMDDC-UHFFFAOYSA-N 0.000 claims 2
- XCHOFVZQFUVVEB-UHFFFAOYSA-N 6-(3-chlorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC(Cl)=C1 XCHOFVZQFUVVEB-UHFFFAOYSA-N 0.000 claims 2
- NAQUDAIOMWNXJF-UHFFFAOYSA-N 6-(3-fluorophenyl)-4-methyl-1,4-dihydro-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)OC(=S)NC2=CC=C1C1=CC=CC(F)=C1 NAQUDAIOMWNXJF-UHFFFAOYSA-N 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 210000004696 endometrium Anatomy 0.000 claims 2
- 230000012173 estrus Effects 0.000 claims 2
- LAQPNDIUHRHNCV-UHFFFAOYSA-N isophthalonitrile Chemical compound N#CC1=CC=CC(C#N)=C1 LAQPNDIUHRHNCV-UHFFFAOYSA-N 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 230000002632 myometrial effect Effects 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 230000001817 pituitary effect Effects 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- JHWNSFIRRIBDRF-UHFFFAOYSA-N tert-butyl 2-cyano-5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)pyrrole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 JHWNSFIRRIBDRF-UHFFFAOYSA-N 0.000 claims 2
- GSXCEVHRIVLFJV-UHFFFAOYSA-N thiophene-3-carbonitrile Chemical compound N#CC=1C=CSC=1 GSXCEVHRIVLFJV-UHFFFAOYSA-N 0.000 claims 2
- WGSXKYXKAARAKD-UHFFFAOYSA-N 1-fluoro-3-isocyanato-5-(trifluoromethyl)benzene Chemical group FC1=CC(N=C=O)=CC(C(F)(F)F)=C1 WGSXKYXKAARAKD-UHFFFAOYSA-N 0.000 claims 1
- VMRFICRSRPCJAO-UHFFFAOYSA-N 1-methyl-5-(2-sulfanylidenespiro[1h-3,1-benzoxazine-4,1'-cyclobutane]-6-yl)pyrrole-2-carbonitrile Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC23CCC3)C2=C1 VMRFICRSRPCJAO-UHFFFAOYSA-N 0.000 claims 1
- JTUBUTWMKWNMTE-UHFFFAOYSA-N 1-methyl-5-(2-sulfanylidenespiro[1h-3,1-benzoxazine-4,1'-cyclopentane]-6-yl)pyrrole-2-carbonitrile Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC23CCCC3)C2=C1 JTUBUTWMKWNMTE-UHFFFAOYSA-N 0.000 claims 1
- HFXYEKNIBXVEDM-UHFFFAOYSA-N 1-methyl-5-[2-sulfanylidene-4,4-bis(trifluoromethyl)-1h-3,1-benzoxazin-6-yl]pyrrole-2-carbonitrile Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C(F)(F)F)C(F)(F)F)C2=C1 HFXYEKNIBXVEDM-UHFFFAOYSA-N 0.000 claims 1
- DCBOJAHTRJNPIJ-UHFFFAOYSA-N 2-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)thiophene-3-carbonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C=1SC=CC=1C#N DCBOJAHTRJNPIJ-UHFFFAOYSA-N 0.000 claims 1
- LTTWZTLIENERDL-UHFFFAOYSA-N 2-[6-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)pyridin-2-yl]acetonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC(CC#N)=N1 LTTWZTLIENERDL-UHFFFAOYSA-N 0.000 claims 1
- GMQRDVATRSGMLF-UHFFFAOYSA-N 3-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-4-fluorobenzonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(C#N)=CC=C1F GMQRDVATRSGMLF-UHFFFAOYSA-N 0.000 claims 1
- CTTIMHOODJRMMQ-UHFFFAOYSA-N 3-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-5-methoxybenzonitrile Chemical compound COC1=CC(C#N)=CC(C=2C=C3C(C)(C)OC(=S)NC3=CC=2)=C1 CTTIMHOODJRMMQ-UHFFFAOYSA-N 0.000 claims 1
- NGXWFLCNLTYJKI-UHFFFAOYSA-N 3-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-5-methylbenzonitrile Chemical compound CC1=CC(C#N)=CC(C=2C=C3C(C)(C)OC(=S)NC3=CC=2)=C1 NGXWFLCNLTYJKI-UHFFFAOYSA-N 0.000 claims 1
- HDYOFEAGTBBGEN-UHFFFAOYSA-N 3-chloro-5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)benzonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(Cl)=CC(C#N)=C1 HDYOFEAGTBBGEN-UHFFFAOYSA-N 0.000 claims 1
- XURBBVPMTVGZEP-UHFFFAOYSA-N 3-fluoro-5-(2-sulfanylidenespiro[1h-3,1-benzoxazine-4,1'-cyclohexane]-6-yl)benzonitrile Chemical compound FC1=CC(C#N)=CC(C=2C=C3C4(CCCCC4)OC(=S)NC3=CC=2)=C1 XURBBVPMTVGZEP-UHFFFAOYSA-N 0.000 claims 1
- COIUOECSBDDSNQ-UHFFFAOYSA-N 4,4-diethyl-6-(3-nitrophenyl)-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(CC)(CC)OC(=S)NC2=CC=C1C1=CC=CC([N+]([O-])=O)=C1 COIUOECSBDDSNQ-UHFFFAOYSA-N 0.000 claims 1
- DCXHYBSZULGYNI-UHFFFAOYSA-N 4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=CC=C2C(C)(C)OC(=S)NC2=C1 DCXHYBSZULGYNI-UHFFFAOYSA-N 0.000 claims 1
- YXZAVJPXYUAVKV-UHFFFAOYSA-N 4-(2-sulfanylidenespiro[1h-3,1-benzoxazine-4,1'-cyclohexane]-6-yl)thiophene-2-carbonitrile Chemical compound O1C(=S)NC2=CC=C(C=3C=C(SC=3)C#N)C=C2C21CCCCC2 YXZAVJPXYUAVKV-UHFFFAOYSA-N 0.000 claims 1
- VSPMRIXKBGUPJW-UHFFFAOYSA-N 4-butyl-5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)thiophene-2-carbonitrile Chemical compound C1=C(C#N)SC(C=2C=C3C(C)(C)OC(=S)NC3=CC=2)=C1CCCC VSPMRIXKBGUPJW-UHFFFAOYSA-N 0.000 claims 1
- UKMZDGICTYHTEO-UHFFFAOYSA-N 4-methyl-5-(2-sulfanylidenespiro[1h-3,1-benzoxazine-4,1'-cyclohexane]-6-yl)thiophene-2-carbonitrile Chemical compound C1=C(C#N)SC(C=2C=C3C4(CCCCC4)OC(=S)NC3=CC=2)=C1C UKMZDGICTYHTEO-UHFFFAOYSA-N 0.000 claims 1
- KBUBDEWGNXRLKX-UHFFFAOYSA-N 5-(2-sulfanylidenespiro[1h-3,1-benzoxazine-4,1'-cyclohexane]-6-yl)thiophene-2-carbonitrile Chemical compound O1C(=S)NC2=CC=C(C=3SC(=CC=3)C#N)C=C2C21CCCCC2 KBUBDEWGNXRLKX-UHFFFAOYSA-N 0.000 claims 1
- XHLKPIQEIXNOQX-UHFFFAOYSA-N 5-(4,4-diethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-1-methylpyrrole-2-carbonitrile Chemical compound C1=C2C(CC)(CC)OC(=S)NC2=CC=C1C1=CC=C(C#N)N1C XHLKPIQEIXNOQX-UHFFFAOYSA-N 0.000 claims 1
- BCDNJBDJBGOTIA-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-1h-pyrrole-2-carbothioamide Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(C(N)=S)N1 BCDNJBDJBGOTIA-UHFFFAOYSA-N 0.000 claims 1
- QLNYJNLJIJPEAO-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-2-fluorobenzonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(F)C(C#N)=C1 QLNYJNLJIJPEAO-UHFFFAOYSA-N 0.000 claims 1
- NUQMIQUEODQESK-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)furan-2-carbonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(C#N)O1 NUQMIQUEODQESK-UHFFFAOYSA-N 0.000 claims 1
- OZHNXRYXILKKOW-UHFFFAOYSA-N 5-(4-ethyl-4-methyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-1-methylpyrrole-2-carbonitrile Chemical compound C1=C2C(CC)(C)OC(=S)NC2=CC=C1C1=CC=C(C#N)N1C OZHNXRYXILKKOW-UHFFFAOYSA-N 0.000 claims 1
- WVQKUAAPNOSAJW-UHFFFAOYSA-N 6-(2,3-difluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC(F)=C1F WVQKUAAPNOSAJW-UHFFFAOYSA-N 0.000 claims 1
- GQLJJGUGKUYGRM-UHFFFAOYSA-N 6-(2-fluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC=C1F GQLJJGUGKUYGRM-UHFFFAOYSA-N 0.000 claims 1
- SMBQGFBYNMMQJM-UHFFFAOYSA-N 6-(3,4-difluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(F)C(F)=C1 SMBQGFBYNMMQJM-UHFFFAOYSA-N 0.000 claims 1
- KTBKDGMHHINKLK-UHFFFAOYSA-N 6-(3,5-difluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(F)=CC(F)=C1 KTBKDGMHHINKLK-UHFFFAOYSA-N 0.000 claims 1
- BUGHELVCJWKCPY-UHFFFAOYSA-N 6-(3-bromo-5-fluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(F)=CC(Br)=C1 BUGHELVCJWKCPY-UHFFFAOYSA-N 0.000 claims 1
- WUJWTXWFRXJYKR-UHFFFAOYSA-N 6-(3-bromo-5-methylphenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound CC1=CC(Br)=CC(C=2C=C3C(C)(C)OC(=S)NC3=CC=2)=C1 WUJWTXWFRXJYKR-UHFFFAOYSA-N 0.000 claims 1
- JGZLNKUOAMAIAG-UHFFFAOYSA-N 6-(3-chloro-5-fluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(F)=CC(Cl)=C1 JGZLNKUOAMAIAG-UHFFFAOYSA-N 0.000 claims 1
- YBBTTYFZWTXGQD-UHFFFAOYSA-N 6-(3-chlorophenyl)-4-methyl-4-phenyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C=3C=CC=CC=3)OC(=S)NC2=CC=C1C1=CC=CC(Cl)=C1 YBBTTYFZWTXGQD-UHFFFAOYSA-N 0.000 claims 1
- UMQGDADSFKJZKD-UHFFFAOYSA-N 6-(3-methoxyphenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound COC1=CC=CC(C=2C=C3C(C)(C)OC(=S)NC3=CC=2)=C1 UMQGDADSFKJZKD-UHFFFAOYSA-N 0.000 claims 1
- PIVCHRZUHMHWMD-UHFFFAOYSA-N 6-(4-fluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(F)C=C1 PIVCHRZUHMHWMD-UHFFFAOYSA-N 0.000 claims 1
- FXVPGONKQHRTRT-UHFFFAOYSA-N 6-[3-bromo-5-(trifluoromethoxy)phenyl]-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(Br)=CC(OC(F)(F)F)=C1 FXVPGONKQHRTRT-UHFFFAOYSA-N 0.000 claims 1
- KWEKPTTVUMVEHM-UHFFFAOYSA-N 6-[3-fluoro-5-(trifluoromethyl)phenyl]-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(F)=CC(C(F)(F)F)=C1 KWEKPTTVUMVEHM-UHFFFAOYSA-N 0.000 claims 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010065701 Dermatillomania Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000009675 Perioral Dermatitis Diseases 0.000 description 1
- 208000001818 Pseudofolliculitis barbae Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
- A61Q7/02—Preparations for inhibiting or slowing hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Birds (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39188502P | 2002-06-25 | 2002-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200410407B true ZA200410407B (en) | 2007-07-25 |
Family
ID=30000769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200410407A ZA200410407B (en) | 2002-06-25 | 2004-12-23 | Cyclothiocarbamative derivatives as PR modulators and use thereof for treatment of skin disorders |
Country Status (19)
Country | Link |
---|---|
US (1) | US7268149B2 (es) |
EP (1) | EP1531824A4 (es) |
JP (1) | JP2005535628A (es) |
KR (1) | KR20050013627A (es) |
CN (1) | CN1665510A (es) |
AR (1) | AR040644A1 (es) |
AU (1) | AU2003245657A1 (es) |
BR (1) | BR0312039A (es) |
CA (1) | CA2489815A1 (es) |
CO (1) | CO5680439A2 (es) |
CR (1) | CR7608A (es) |
EC (1) | ECSP055572A (es) |
IL (1) | IL165397A0 (es) |
MX (1) | MXPA04012420A (es) |
NO (1) | NO20045214L (es) |
RU (1) | RU2005101625A (es) |
TW (1) | TW200400950A (es) |
WO (1) | WO2004000230A2 (es) |
ZA (1) | ZA200410407B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355648B1 (en) * | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
US6407101B1 (en) | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
UA73119C2 (en) * | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
BR0312054A (pt) * | 2002-06-25 | 2005-10-18 | Wyeth Corp | Uso de derivados de tio-oxindol na preparação de medicamentos úteis no tratamento de condições relacionadas com hormÈnio, e kit farmacêutico |
CN1938298B (zh) * | 2004-04-08 | 2013-02-06 | 惠氏公司 | 减少硫代酰胺杂质的方法 |
JP4869221B2 (ja) * | 2004-04-08 | 2012-02-08 | ワイス・エルエルシー | プロゲステロン受容体調節剤としてのチオアミド誘導体 |
BRPI0510260A (pt) * | 2004-04-27 | 2007-10-23 | Wyeth Corp | método para purificar um composto, e, kit farmacêutico |
CA2562160C (en) * | 2004-04-27 | 2013-05-28 | Wyeth | Cyanopyrrole containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same |
PA8638601A1 (es) * | 2004-07-07 | 2006-07-03 | Wyeth Corp | Regimenes y kits de progestina ciclica |
BRPI0514273A (pt) * | 2004-08-13 | 2008-06-10 | Wyeth Corp | composto, kit para monitorar terapia com tanaproget, método para detectar metabólitos de tanaproget, anticorpo, composição, kit para detectar metabólicos de tanaproget, e, uso de um derivado de glucuronìdeo de tanaproget ou um seu sal farmaceuticamente aceitável |
US7496489B2 (en) | 2004-08-20 | 2009-02-24 | Wyeth | Design of progesterone receptor ligands |
WO2006116514A2 (en) * | 2005-04-28 | 2006-11-02 | Wyeth | Micronized tanaproget, compositions, and methods of preparing the same |
ES2340518T3 (es) * | 2005-04-28 | 2010-06-04 | Wyeth Llc | Tanaproget micronizado y composiciones que lo contienen. |
CN101166521A (zh) | 2005-04-28 | 2008-04-23 | 惠氏公司 | 通过湿制粒法制备包含微粒化他那普戈特的组合物 |
WO2006116498A2 (en) * | 2005-04-28 | 2006-11-02 | Wyeth | Purified form of tanaproget |
CN101166736B (zh) * | 2005-04-28 | 2013-02-06 | 惠氏公司 | 他那普戈特的多晶型ⅱ |
WO2006135638A2 (en) * | 2005-06-09 | 2006-12-21 | Wyeth | Tanaproget compositions containing ethinyl estradiol |
AU2007338102A1 (en) * | 2006-12-22 | 2008-07-03 | F. Hoffmann-La Roche Ag | Processes for the preparation of (3R, 4R) -N- (4 -chlorophenyl) -1- (2, 2-difluoroethyl) -N' - [2-fluoro-4- (2-oxo-1 (2H) -pyridinyl) phenyl] -3, 4-pyrrolidinedicarboxamide |
BRPI0819571A2 (pt) * | 2007-12-20 | 2019-09-24 | Teva Womenss Health Inc | "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica" |
DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
EP2664325A1 (en) * | 2012-05-16 | 2013-11-20 | PregLem S.A. | Methods for preventing or treating androgen mediated diseases |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0155934B1 (en) * | 1983-07-29 | 1989-12-06 | Duke University | Pharmaceutical compositions for treating androgen-related disorders in humans |
GB2310660A (en) * | 1996-03-01 | 1997-09-03 | Merck & Co Inc | Benzoxazinone oxytocin receptor antagonists |
DK1123082T3 (da) * | 1998-10-23 | 2006-06-26 | Aventis Pharma Sa | Præparater til topisk applikation af antiandrogent aktive forbindelser |
US6355648B1 (en) * | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
US6509334B1 (en) * | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
US6407101B1 (en) * | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
WO2001015108A1 (en) | 1999-08-26 | 2001-03-01 | Automotive Systems Lyboratory, Inc. | Magnetic sensor |
US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
TR200200507T2 (tr) * | 1999-08-27 | 2002-10-21 | Ligand Pharmaceuticals Inc | Androjen reseptörü modülatör bileşikleri ve metotları |
OA12245A (en) | 2000-04-10 | 2003-11-10 | Pfizer Prod Inc | Benzoamide piperidine compounds as substance P antagonists. |
US7119207B2 (en) * | 2000-04-10 | 2006-10-10 | Pfizer Inc | Benzoamide piperidine containing compounds and related compounds |
UA73119C2 (en) * | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
-
2003
- 2003-06-23 BR BR0312039-2A patent/BR0312039A/pt not_active IP Right Cessation
- 2003-06-23 MX MXPA04012420A patent/MXPA04012420A/es unknown
- 2003-06-23 CN CN038151944A patent/CN1665510A/zh active Pending
- 2003-06-23 US US10/601,968 patent/US7268149B2/en not_active Expired - Fee Related
- 2003-06-23 CA CA002489815A patent/CA2489815A1/en not_active Abandoned
- 2003-06-23 AU AU2003245657A patent/AU2003245657A1/en not_active Abandoned
- 2003-06-23 EP EP03739286A patent/EP1531824A4/en not_active Withdrawn
- 2003-06-23 WO PCT/US2003/019860 patent/WO2004000230A2/en not_active Application Discontinuation
- 2003-06-23 RU RU2005101625/04A patent/RU2005101625A/ru not_active Application Discontinuation
- 2003-06-23 TW TW092116986A patent/TW200400950A/zh unknown
- 2003-06-23 IL IL16539703A patent/IL165397A0/xx unknown
- 2003-06-23 JP JP2004516187A patent/JP2005535628A/ja active Pending
- 2003-06-23 AR AR20030102239A patent/AR040644A1/es not_active Application Discontinuation
- 2003-06-23 KR KR10-2004-7021150A patent/KR20050013627A/ko not_active Application Discontinuation
-
2004
- 2004-11-29 NO NO20045214A patent/NO20045214L/no not_active Application Discontinuation
- 2004-12-08 CR CR7608A patent/CR7608A/es not_active Application Discontinuation
- 2004-12-23 ZA ZA200410407A patent/ZA200410407B/en unknown
-
2005
- 2005-01-20 CO CO05004456A patent/CO5680439A2/es not_active Application Discontinuation
- 2005-01-25 EC EC2005005572A patent/ECSP055572A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CR7608A (es) | 2006-07-14 |
JP2005535628A (ja) | 2005-11-24 |
CO5680439A2 (es) | 2006-09-29 |
KR20050013627A (ko) | 2005-02-04 |
WO2004000230A2 (en) | 2003-12-31 |
EP1531824A2 (en) | 2005-05-25 |
IL165397A0 (en) | 2006-01-15 |
MXPA04012420A (es) | 2005-04-19 |
US7268149B2 (en) | 2007-09-11 |
BR0312039A (pt) | 2005-06-28 |
RU2005101625A (ru) | 2005-06-27 |
ECSP055572A (es) | 2005-04-18 |
EP1531824A4 (en) | 2005-09-21 |
NO20045214L (no) | 2005-03-17 |
CN1665510A (zh) | 2005-09-07 |
AU2003245657A1 (en) | 2004-01-06 |
AR040644A1 (es) | 2005-04-13 |
US20040014798A1 (en) | 2004-01-22 |
TW200400950A (en) | 2004-01-16 |
WO2004000230A3 (en) | 2004-04-29 |
CA2489815A1 (en) | 2003-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200410407B (en) | Cyclothiocarbamative derivatives as PR modulators and use thereof for treatment of skin disorders | |
RU2005101638A (ru) | Использование циклокарбаматных производных для лечения гормонзависимых состояний | |
ES2386786T3 (es) | Método para tratar rubor cutáneo usando agonistas selectivos de receptores alpha-2-adrenérgicos. | |
SK14762003A3 (sk) | Kožou prestupujúci prípravok obsahujúci selektívne inhibujúcu cyklooxygenázu-2 a jednosýtny alkohol | |
JP2012087129A5 (es) | ||
TW200401637A (en) | Use of thio-oxindole derivatives in treatment of skin disorders | |
US20040127531A1 (en) | Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor | |
TW200817378A (en) | Compositions and methods for treating or preventing glaucoma or progression thereof | |
US20040126415A1 (en) | Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor | |
TW200425915A (en) | Selective cyclooxygenase-2 inhibitor patch | |
JP2022529661A (ja) | ジスキネジア治療薬 | |
JPH07110806B2 (ja) | 脱毛症を治療するための組成物 | |
RU2009127776A (ru) | Профилактическое или терапевтическое средство от алопеции | |
BE1003002A6 (fr) | Composition a mettre en oeuvre pour le traitement de la calvitie, et procedes faisant usage de celle-ci. | |
CA2824996A1 (en) | Compounds and methods for enhancing hair growth | |
JP2004517853A5 (es) | ||
JPWO2021229152A5 (es) | ||
AU3948699A (en) | Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation | |
JP2024100696A (ja) | 育毛組成物 | |
ES2286920B1 (es) | Derivados de aril (o heteroaril)azolilcarbinoles para el tratamiento de la fibromialgia. | |
WO2021087074A1 (en) | Therapeutic formulations and uses thereof | |
TW200403989A (en) | Methods and compositions for treatment of cancer pain | |
MX2008002908A (es) | Inhibidores de ikk para el tratamiento de endometriosis | |
WO2006115193A1 (ja) | 黄色腫治療剤 | |
Cimberle | Intracameral delivery of mydriatics shows promise, surgeons say |